Alfosbuvir plus Daclatasvir for Treatment of Chronic Hepatitis C Virus Infection in China

Daclatasvir Regimen Sofosbuvir Clinical endpoint
DOI: 10.1007/s40121-023-00872-4 Publication Date: 2023-10-19T04:02:13Z
ABSTRACT
A pan-genotypic and effective treatment regimen for patients with chronic hepatitis C virus (HCV) infection remains an unmet medical need in China. Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor development the of infection. We conducted phase 3 study to evaluate efficacy safety alfosbuvir combination daclatasvir Chinese All received 600 mg tablets plus 60 once daily 12 weeks. The primary endpoint was sustained virological response weeks after end (SVR12). follow-up visit done at week 4 12, those who achieved SVR12 were followed up post-treatment 24. Of 326 least one dose drug, 320 (98.2% [95% confidence interval (CI): 96.5%–99.5%]) (SVR12), which superior historical rate 88% (p < 0.0001). rates similar regardless most baseline characteristics. common adverse event (AE) (≥ 10%) hypercholesterolemia. Serious events (SAEs) reported 25 (7.7%) patients, none judged be related drug. majority AEs mild moderate severity. highly safe infected genotype 1, 2, 3, or 6, suggesting that this could promising option China irrespective genotype. ClinicalTrial.gov identifier, NCT04070235.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (24)
CITATIONS (2)